. "NAD(+--diphthamide ADP- ribosyltransferase)"@en . . . "DT"@en . . . . "# Turturro F: Denileukin diftitox: a biotherapeutic paradigm shift in the treatment of lymphoid-derived disorders. Expert Rev Anticancer Ther. 2007 Jan;7(1):11-7. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17187516 # Park M, Liu GT, Piltz-Seymour J, Wisda CL, Rook AH, Junkins-Hopkins JM, Nasta SD, Kim EJ: Vision loss following denileukin diftitox treatment: a case report of possible posterior ischemic optic neuropathy. Leuk Lymphoma. 2007 Apr;48(4):808-11. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17454642"@en . . "173146-27-5"@en . " "@en . "* 0.06 to 0.09 L/kg"@en . "For treatment of cutaneous T-cell lymphoma"@en . . "Denileukin diftitox"@en . "investigational"@en . . "Denileukin diftitox binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells."@en . . . "Diphtheria toxin precursor"@en . . "approved"@en . . . "70-80 min"@en . . . . "A recombinant DNA-derived cytotoxic protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met 1-Thr 387)-His followed by the sequences for interleukin-2 (IL-2; Ala 1-Thr 133). It is produced in an E. coli expression system."@en . "* 0.6 - 2.0 mL/min/kg [Lymphoma]"@en . . . . "Humans and other mammals"@en . . .